Format

Send to:

Choose Destination
See comment in PubMed Commons below
Minerva Med. 2009 Oct;100(5):371-83.

Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.

Author information

  • 1Moffitt Cancer Center and Research Institute, Division of Cancer Prevention and Control, Tampa, FL, USA. gwen.quinn@moffitt.org

Abstract

The lifetime risks for both breast and ovarian cancer for BRCA mutation carriers far exceeds the general population risk of 13% for breast cancer and 1.4% for ovarian cancer. BRCA carriers have unique and medically complicated decisions to make regarding their cancer treatment or risk reduction. As BRCA testing becomes increasingly common among unaffected individuals in families with a previously documented BRCA mutation, there are a growing number of individuals with unique psychosocial needs and concerns. This review paper describes the BRCA 1/2 population, discusses preimplantation genetic diagnosis (PGD), and describes the decisions and ethical issues related to PGD among the BRCA 1/ 2 population.

PMID:
19910890
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Minerva Medica
    Loading ...
    Write to the Help Desk